What is Perrigo Company's pain & sleep — net sales?

Perrigo Company (PRGO) reported pain & sleep — net sales of $106.6M in Q1 2026.

What does pain & sleep — net sales mean?

This metric represents the total revenue generated from the sale of over-the-counter pain relief and sleep aid products within the company's consumer healthcare portfolio. It reflects the market demand for self-care solutions in the analgesic and sleep-support categories, serving as a key indicator of segment-specific growth and consumer brand loyalty. Tracking this figure allows investors to assess the performance of the company's therapeutic offerings against broader consumer health trends.

Perrigo Company PRGO Pain & Sleep — Net Sales

Other product segments

Oral Care

$354.4M-5.4%

Upper Respiratory

$197.4M-8.1%

Skin Health

$151.9M—

Healthy Lifestyle

$142.7M-9.1%

Digestive Health

$96.6M-14.4%

Women's Health

$55.1M+11.3%

Similar metrics at other companies

AVNSTotal Pain Management and Recovery — Net Sales

$56.3M+0.2%

AVNSSurgical pain and recovery — Net Sales

$21.8M-11.0%

AHCOSleep Health — Net revenue

$358.5M+13.3%

RMDSleep And Breathing Health — Net revenue by segment

$1.26B+11.5%

CRISleepwear — Net Sales

$87.9M-5.8%

PBH

PBHAnalgesics — Total revenues

$28.24M-6.5%

Other financials

Income statement

See full

Revenue$969.2M-7.2%

Gross profit$325.5M-17.0%

Operating income-$372.3M-894%

Net income-$398.6M-6,128%

EPS (diluted)-$2.87-5,640%

Balance sheet

See full

Cash & equivalents$357.2M-12.9%

Total debt$3.8B-0.6%

Total equity$2.5B-42.7%

Total assets$8.0B-18.2%

Cash flow

See full

Operating cash flow-$113.6M-76.1%

CapEx$13.8M-45.9%

Free cash flow-$127.4M-41.6%

Valuation

See full

Market cap$1.35B-62.9%

Enterprise value$4.82B-32.0%

P/S0.3×-0.5×

Profitability

See full

Gross margin34.2%-2.2pp

Operating margin-36.9%-41.8pp

Net margin-43.5%-48.6pp

FCF margin4.2%-2.0pp

Returns & leverage

See full

Return on equity-53%-57.7pp

Debt / equity1.5×+0.6×

Current ratio2.7×+0.4×

Where this comes from

Reported directly by Perrigo Company in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Perrigo Company’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perrigo Company's pain & sleep — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perrigo Company's pain & sleep — net sales?: Perrigo Company (PRGO) reported pain & sleep — net sales of $106.6M in Q1 2026.
What does pain & sleep — net sales mean?: This metric represents the total revenue generated from the sale of over-the-counter pain relief and sleep aid products within the company's consumer healthcare portfolio. It reflects the market demand for self-care solutions in the analgesic and sleep-support categories, serving as a key indicator of segment-specific growth and consumer brand loyalty. Tracking this figure allows investors to assess the performance of the company's therapeutic offerings against broader consumer health trends.